PROTAC CDK9 degrader-12 

PROTAC CDK9 degrader-12 is a selective CDK9 PROTAC degrader with a DC₅₀ of 23 nM. PROTAC CDK9 degrader-12 induces proteasome-dependent degradation of CDK9, blocks CDK9-mediated HIV-1 transcriptional elongation, and reduces HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is applicable to research related to HIV-1 infection^[1]. (Pink: CDK9 ligand (HY-181275); Blue: VHL ligand (HY-120217); Black: linker).

PROTAC CDK9 degrader-12 (1.0 μM, unspecified serial dilutions; variable times) potently inhibits HIV-1 replication in SupT1 cells (IC₅₀ = 78.92 nM) with a high selectivity index (531), acting by blocking CDK9-mediated HIV-1 transcription elongation, and its anti-HIV-1 activity is dependent on wild-type CDK9 degradation^[1].
PROTAC CDK9 degrader-12 (10 μM; 24 h) exhibits no obvious cytotoxicity in HepG2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1175.51

C₆₀H₈₂N₁₄O₇S₂

3052648-82-2

CC1=C(C2=CC=C(CNC([C@@H]3C[C@@H](O)CN3C([C@@H](NC(CCCCCCCCCCN4N=NC(CN5CCN(S(=O)(C6=CC=C(NC7=NC8=C(C=N7)C=C(C(N(C)C)=O)N8C9CCCC9)C=C6)=O)CC5)=C4)=O)C(C)(C)C)=O)=O)C=C2)SC=N1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yang B, et al. A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis. Mol Divers. Published online November 12, 2025.  [Content Brief]